| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A critical moment for health care
|
The Lancet Respiratory Medicine,
|
|
|
9 |
12 |
p. 1343
|
artikel
|
| 2 |
Awake prone positioning for COVID-19 acute hypoxaemic respiratory failure: a randomised, controlled, multinational, open-label meta-trial
|
Ehrmann, Stephan
|
|
|
9 |
12 |
p. 1387-1395
|
artikel
|
| 3 |
Awake prone positioning in COVID-19: is tummy time ready for prime time?
|
Weatherald, Jason
|
|
|
9 |
12 |
p. 1347-1349
|
artikel
|
| 4 |
Baricitinib: the first immunomodulatory treatment to reduce COVID-19 mortality in a placebo-controlled trial
|
Kalil, Andre C
|
|
|
9 |
12 |
p. 1349-1351
|
artikel
|
| 5 |
Breathing lessons: a doctor's guide to lung health
|
Paterson, Bri
|
|
|
9 |
12 |
p. 1362
|
artikel
|
| 6 |
Charting a course for the management of long COVID
|
Beasley, Richard
|
|
|
9 |
12 |
p. 1358-1360
|
artikel
|
| 7 |
Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
|
|
|
|
9 |
12 |
p. 1419-1426
|
artikel
|
| 8 |
Colchicine treatment in COVID-19: the remaining unsolved question
|
Rojas-Villarraga, Adriana
|
|
|
9 |
12 |
p. 1351-1353
|
artikel
|
| 9 |
Correction to Lancet Respir Med 2021; 9: 340–42
|
|
|
|
9 |
12 |
p. e114
|
artikel
|
| 10 |
Correction to Lancet Respir Med 2019; 7: 745–56
|
|
|
|
9 |
12 |
p. e114
|
artikel
|
| 11 |
Correction to Lancet Respir Med 2021; 9: 1377–86
|
|
|
|
9 |
12 |
p. e114
|
artikel
|
| 12 |
Correction to Lancet Respir Med 2021; published online Nov 9. https://doi.org/10.1016/S2213-2600(21)00414-8
|
|
|
|
9 |
12 |
p. e114
|
artikel
|
| 13 |
Correction to Lancet Respir Med 2021; published online Oct 1. https://doi.org/10.1016/S2213-2600(21)00352-0
|
|
|
|
9 |
12 |
p. e114
|
artikel
|
| 14 |
COVID-19 hospital admissions and deaths after BNT162b2 and ChAdOx1 nCoV-19 vaccinations in 2·57 million people in Scotland (EAVE II): a prospective cohort study
|
Agrawal, Utkarsh
|
|
|
9 |
12 |
p. 1439-1449
|
artikel
|
| 15 |
COVID-19-related ARDS: one disease, two trajectories, and several unanswered questions
|
Lascarrou, Jean-Baptiste
|
|
|
9 |
12 |
p. 1345-1347
|
artikel
|
| 16 |
Does infection with or vaccination against SARS-CoV-2 lead to lasting immunity?
|
Milne, Gregory
|
|
|
9 |
12 |
p. 1450-1466
|
artikel
|
| 17 |
Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial
|
Declercq, Jozefien
|
|
|
9 |
12 |
p. 1427-1438
|
artikel
|
| 18 |
Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial
|
Marconi, Vincent C
|
|
|
9 |
12 |
p. 1407-1418
|
artikel
|
| 19 |
Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-blind, randomised, placebo-controlled, phase 3 trial
|
Kalil, Andre C
|
|
|
9 |
12 |
p. 1365-1376
|
artikel
|
| 20 |
Global tuberculosis progress reversed by COVID-19 pandemic
|
Kirby, Tony
|
|
|
9 |
12 |
p. e118-e119
|
artikel
|
| 21 |
Has Spain reached herd immunity?
|
Kirby, Tony
|
|
|
9 |
12 |
p. e120
|
artikel
|
| 22 |
Invisible demons
|
Burki, Talha Khan
|
|
|
9 |
12 |
p. 1362-1363
|
artikel
|
| 23 |
Longitudinal respiratory subphenotypes in patients with COVID-19-related acute respiratory distress syndrome: results from three observational cohorts
|
Bos, Lieuwe D J
|
|
|
9 |
12 |
p. 1377-1386
|
artikel
|
| 24 |
Long-term outcomes of EVALI: a 1-year retrospective study
|
Triantafyllou, Georgios A
|
|
|
9 |
12 |
p. e112-e113
|
artikel
|
| 25 |
Nintedanib for treating progressive fibrosing interstitial lung diseases
|
Adler, Amanda I
|
|
|
9 |
12 |
p. e116-e117
|
artikel
|
| 26 |
Philip Morris International purchases Vectura
|
Burki, Talha Khan
|
|
|
9 |
12 |
p. e122
|
artikel
|
| 27 |
Prone positioning might reduce the need for intubation in people with severe COVID-19
|
McGuire, W Cameron
|
|
|
9 |
12 |
p. e110
|
artikel
|
| 28 |
Prone positioning might reduce the need for intubation in people with severe COVID-19 – Authors' reply
|
Ibarra-Estrada, Miguel
|
|
|
9 |
12 |
p. e111
|
artikel
|
| 29 |
Safety and immunogenicity of CpG 1018 and aluminium hydroxide-adjuvanted SARS-CoV-2 S-2P protein vaccine MVC-COV1901: interim results of a large-scale, double-blind, randomised, placebo-controlled phase 2 trial in Taiwan
|
Hsieh, Szu-Min
|
|
|
9 |
12 |
p. 1396-1406
|
artikel
|
| 30 |
Severe breakthrough COVID-19 infections in Scotland—implications for immunisation programmes
|
Leshem, Eyal
|
|
|
9 |
12 |
p. 1354-1356
|
artikel
|
| 31 |
Subcutaneous interferon beta-1a in COVID-19: raking the ashes of an intervention trial
|
Wilkinson, Tom
|
|
|
9 |
12 |
p. 1344-1345
|
artikel
|
| 32 |
The course of action for effective anti-cytokine treatment in COVID-19
|
Cavalli, Giulio
|
|
|
9 |
12 |
p. 1353-1354
|
artikel
|
| 33 |
The first wave
|
Burki, Talha Khan
|
|
|
9 |
12 |
p. 1361
|
artikel
|
| 34 |
The long-term sequelae of COVID-19: an international consensus on research priorities for patients with pre-existing and new-onset airways disease
|
Adeloye, Davies
|
|
|
9 |
12 |
p. 1467-1478
|
artikel
|
| 35 |
Undetected COVID-19 cases in Africa
|
Burki, Talha Khan
|
|
|
9 |
12 |
p. e121
|
artikel
|
| 36 |
US FDA delays decision on Juul and other leading e-cigarette brands
|
Furlow, Bryant
|
|
|
9 |
12 |
p. e115
|
artikel
|
| 37 |
Venus and Mars: chest wall deformity and thoracic disease
|
Ashrafian, Hutan
|
|
|
9 |
12 |
p. 1363-1364
|
artikel
|
| 38 |
Waning immunity to SARS-CoV-2: implications for vaccine booster strategies
|
Altmann, Daniel M
|
|
|
9 |
12 |
p. 1356-1358
|
artikel
|
Tijdschrift beschrijving